Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer.

Slides:

Advertisements

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Advertisements

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer Yoichi.

Niv Ad, MD, Linda Henry, PhD, RN, Deborah J. Shuman, BS, Sari D

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database Traves D. Crabtree,

Outcomes of Reintervention on the Autograft After Ross Procedure

Joshua E. Rosen, BASc, Hari B

Phillips B. Harrington, MD, William W. McAlexander, MD, Ayesha S

Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis Andrew J. Graham, MD, MS, Fiona M. Shrive,

Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy Colin Schieman, MD, Dennis A. Wigle, MD, PhD,

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy

Less Is More in Post Pediatric Heart Transplant Care

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Complex Esophageal Reconstruction Procedures Have Acceptable Outcomes Compared With Routine Esophagectomy Jessica M. Moore, BS, Craig M. Hooker, PhD,

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Andrea S. Wolf, MD, MPH, Scott J

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Fate of Functional Mitral Regurgitation and Predictors of Persistent Mitral Regurgitation After Isolated Aortic Valve Replacement Hyun-Chel Joo, MD,

Established Preoperative Risk Factors Do Not Predict Long-Term Survival in Isolated Coronary Artery Bypass Grafting Patients Giovanni Filardo, PhD, MPH,

Lung Cancer Surgery in Patients With Liver Cirrhosis

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Observational Study on the Beneficial Effect of Preoperative Statins in Reducing Atrial Fibrillation After Coronary Surgery Giovanni Mariscalco, MD,

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Impact of Blood Product Transfusion on Short and Long-Term Survival After Cardiac Surgery: More Evidence Balu Bhaskar, MD, FCICM, Joel Dulhunty, PhD,

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Survival After Surgical Resection of Stage IV Esophageal Cancer

Felix G. Fernandez, MD, Onkar Khullar, MD, Seth D

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Matthew J. Bott, MD, Hanghang Wang, BA, William Travis, MD, Gregory J

Kathryn E. Engelhardt, MD, Malcolm M. DeCamp, MD, Anthony D

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response.

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Phillip G. Rowse, MD, Dawn E

William M. Whited, MD, Paul Henley, BS, Erin M

A. Thomas Pezzella, MD, Sari D

Comparison of Neoadjuvant Chemotherapy Followed by Surgery to Upfront Surgery for Thymic Malignancy Samina Park, MD, In Kyu Park, MD, PhD, Young Tae.

Attila Dubecz, MD, Thomas J. Watson, MD, Daniel P

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD,

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Does Timing of Surgical Procedure After Neoadjuvant Chemoradiation Affect Outcomes in Esophageal Cancer? Williams Tessier, MD, Caroline Gronnier, MD,

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Nabin K. Shrestha, MD, MPH, Jennifer Jue, MD, Syed T

Trends in Patient Characteristics and Outcomes of Coronary Artery Bypass Grafting in the 2000 to 2012 Medicare Population Christian McNeely, MD, Stephen.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Luis F. Tapias, MD, Douglas J. Mathisen, MD, Cameron D

Benny Weksler, MD, Manisha Shende, MD, Katie S

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Jenifer L. Marks, MD, Wayne Hofstetter, MD, Arlene M

Presentation transcript:

Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer Q. Zhang, BS, Craig M. Hooker, MPH, Malcolm V. Brock, MD, James Shin, BS, Sue Lee, BS, Remealle How, MD, Noreli Franco, PhD, Helen Prevas, BS, Alicia Hulbert, MD, Stephen C. Yang, MD The Annals of Thoracic Surgery Volume 93, Issue 2, Pages 429-437 (February 2012) DOI: 10.1016/j.athoracsur.2011.10.061 Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Kaplan-Meier curves of overall survival rates for 14 esophageal cancer patients staged as cT2 N0 who underwent operations alone vs 55 cT2 N0 patients who received neoadjuvant chemoradiation therapy, followed by operation, with 5-year survival rates of 49.5% vs 53.8%, respectively. The Annals of Thoracic Surgery 2012 93, 429-437DOI: (10.1016/j.athoracsur.2011.10.061) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Kaplan-Meier curves of recurrence-free survival rates for 10 esophageal cancer patients staged as cT2 N0 who underwent operations alone vs 50 cT2 N0 patients who received neoadjuvant chemoradiation therapy, followed by an operation, with 5-year recurrence-free survival rates of 80% vs 63%, respectively. This analysis excluded 7 patients who were margin-positive and 2 patients with unknown margin status. The Annals of Thoracic Surgery 2012 93, 429-437DOI: (10.1016/j.athoracsur.2011.10.061) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions